<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03757936</url>
  </required_header>
  <id_info>
    <org_study_id>HLX10HLX04-001</org_study_id>
    <nct_id>NCT03757936</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (HLX10) in Combination With Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (HLX04) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the
      safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced
      solid tumors after failure of standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">December 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of HLX04 plus HLX10 in patients with advanced solid tumors</measure>
    <time_frame>28 days</time_frame>
    <description>The MTD is the dose with toxicity rate (estimated by isotonic regression) most approximate to the target one (30%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) of HLX04 plus HLX10 in patients with advanced solid tumors</measure>
    <time_frame>28 days</time_frame>
    <description>DLT is defined as the occurrence of the following adverse events (unless judged by the investigator to be definitely unrelated to HLX04 or HLX10) within Cycle 1 (i.e., from Cycle 1 Day 1 to Cycle 1 Day 28)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of the HLX04 plus HLX10 therapy in patients with advanced solid tumors</measure>
    <time_frame>Day 1 of treatment up to 2 years</time_frame>
    <description>Peak Plasma Concentration (Cmax) for single dose and multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of the HLX04 plus HLX10 therapy in patients with advanced solid tumors</measure>
    <time_frame>Day 1 of treatment up to 2 years</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) for single dose and multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) of HLX04 plus HLX10 in patients with advanced solid tumors</measure>
    <time_frame>Day 1 of treatment up to 2 years</time_frame>
    <description>ORR determined by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) of HLX04 plus HLX10 in patients with advanced solid tumors</measure>
    <time_frame>Day 1 of treatment up to 2 years</time_frame>
    <description>DCR determined by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) of HLX04 plus HLX10 in patients with advanced solid tumors</measure>
    <time_frame>Day 1 of treatment up to 2 years</time_frame>
    <description>DOR determined by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) of HLX04 plus HLX10 in patients with advanced solid tumors</measure>
    <time_frame>Day 1 of treatment up to 2 years</time_frame>
    <description>PFS determined by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) of HLX04 plus HLX10 in patients with advanced solid tumors</measure>
    <time_frame>Day 1 of treatment up to 2 years</time_frame>
    <description>OS determined by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Day 1 of treatment up to 2 years</time_frame>
    <description>Anti-drug Antibody (ADA) Testing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>HLX04+HLX10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX04</intervention_name>
    <description>Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection</description>
    <arm_group_label>HLX04+HLX10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX10</intervention_name>
    <description>Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection</description>
    <arm_group_label>HLX04+HLX10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years, male or female

          2. Patient with histologically or cytologically confirmed advanced malignant solid tumors
             who have failed standard of care, or has no standard-of-care therapy or are not
             suitable for standard of care at the present stage;

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1；

          4. Life expectancy greater than 3 months;

          5. Patient must have at least one measurable tumor lesion as defined by RECIST v1.1; the
             lesion concerned must not be a bone metastasis if only one target lesion is present;

          6. Has adequate organ functions;

          7. If the subject is a patient with hepatocellular carcinoma, Child-Pugh classification
             must be A.

          8. A qualified patient (male or female) of childbearing potential must agree to use
             reliable contraceptive methods (hormonal, or barrier method or abstinence) for the
             course of the study and through at least 6 months after the last dose; a female
             patient of childbearing potential must have negative blood pregnancy test within 7
             days prior to enrollment;

          9. The subject must give his/her informed consent to this study prior to the trial, and
             voluntarily sign a written informed consent form.

        Exclusion Criteria:

          1. Histopathological confirmed head and neck cancer or squamous-cell lung cancer, or
             bleeding tendency in the tumor lesion judged by the investigator;

          2. Has received antitumor therapy like radiotherapy, chemotherapy, targeted therapy,
             endocrinal therapy or immunotherapy, or other clinical study drug therapy within 4
             months prior to the initial drug administration;

          3. Has received a surgical operation on major viscera or experienced apparent trauma
             within 4 weeks from the initial drug administration, or experienced subcutaneous
             venous access device implantation within 7 days;

          4. The adverse reactions which occurred in the previous antitumor treatment were not
             recovered to ≤ grade 1 based on CTCAE 4.03 assessment (except for hair loss);

          5. Evidences of metastatic lesion in the patient's central nervous system;

          6. Previously experienced ≥ grade 3 immune-related adverse event during immunotherapy;

          7. Active, or history of autoimmune disease which may relapse (for example, systemic
             lupus erythematosus, rheumatoid arthritis, vasculitis, etc.);

          8. Currently having or have had interstitial lung disease;

          9. Uncontrollable active infection(s);

         10. History of immunodeficiency, including HIV antibody positive;

         11. Known active hepatitis B; or hepatitis C virus infections;

         12. Has bleeding tendency;

         13. History of severe cardiovascular diseases;

         14. Known gastrointestinal diseases as follows:

             Gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months
             before signing the informed consent; History of poorly controlled or recurrent
             inflammatory bowel disease; Active peptic ulcers, or &gt; moderate esophageal varices;

         15. Known hypersensitivity to Bevacizumab, or other anti-PD-1, anti-PD-L1 monoclonal
             antibody agents;

         16. Pregnant or breastfeeding female.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joanne Wang</last_name>
    <phone>+86-021-33395800-6024</phone>
    <email>Joanne_wang@henlius.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li, MD</last_name>
      <email>lijin@csco.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

